and this site was lost by mutation in each of the seven t(3;14) DLBCL cases ( Figure 2 ). This suggests an active de-selection mechanism operating against glycosylation motifs. Of the V 4-34 cases, 6/7 were non-GCB and one case GCB, reflecting the predominant non-GCB phenotype of t(3;14) DLBCL. The apparent biased selection of V 4-34 -expressing B-cells in these DLBCL may have further implications. The V 4-34 gene is of importance in autoimmune disease, such as in systemic lupus erythematosus and cold agglutinin disease (CAD).
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The fms-like tyrosine kinase 3-FLT3 gene encodes a class 3 receptor tyrosine kinase for the FLT3 ligand, that is normally expressed in CD34 þ hematopoietic stem/progenitor cells and plays a fundamental role in both normal and leukemic hematopoiesis. 1 Tandem internal duplication of the FLT3 gene (FLT3/ITDs) represents one of the most common molecular abnormalities in patients with acute myeloid leukemia (AML), and can be detected in around 25% of all patients. 2 This abnormality consists of in-frame insertions of duplicated sequences localized in the juxtamembrane region of the molecule, and results in the constitutive, ligand independent, activation of the tyrosine kynase activity of the FLT3 receptor; this in turn would be responsible for the abnormal proliferation and differentiation of FLT3 mutated leukemia stem cells.
1 From a clinical point of view, the presence of FLT3/ITDs confers a worse prognosis due to an increased relapse rate, adverse disease-free survival (DFS) and reduced overall survival (OS), while the rate of complete remission (CR) is not significantly affected. 3, 4 The effects on OS are independent of the cytogenetic risk category. 3 The molecular characteristics of FLT3/ITDs are extremely variable among patients because of the different mutated to wild-type (WT) allele ratios and the wide size of duplicated sequences, that range from a few to hundreds of nucleotides (nt). It has been shown that patients with the highest FLT3/ITDs/FLT3
WT ratios, and even more hemizygous FLT3/ITDs patients who lack normal FLT3, 5 present a particularly adverse disease outcome. 3, 5 Furthermore, Stirewalt et al. 6 recently reported that the presence of longer ITDs associated with decreasing OS and RFS, suggesting that FLT3/ITD size may have prognostic significance.
The aim of this study was to evaluate whether determining the size of the FLT3 internal tandem duplication would add to prognosis assessment in a population of adult AML patients diagnosed and treated in our Institution.
We studied 146 adult patients with AML, median age 52, range 21-69 years; 88 (60%) were females. The only criteria for inclusion in the study was the availability of a molecular typing for FLT3/ITDs. According to FAB classifications, there were 7 M0, 23 M1, 41 M2, 48 M4, 21 M5, 3 M6 and 3 patients with M7 AML; patients with acute promyelocytic FAB-M3 leukemia were not included. Based on conventional karyotyping, 17 patients (12%) were in the low-risk category, while 69 (47%) and 28 (19%) were in the intermediate and high-risk category, respectively; in 32 patients (22%) karyotyping could not be successfully performed. Patients were treated according to two conventional induction regimens: 72 of them (49%) received Ida-FLA regimen (Fludarabine 25 mg/m 2 on days 1-4; Cytarabine 2 g/m 2 on days 1-4; Idarubicin 12 mg/m 2 on days 1-3 in patients younger than 65 years and 8 mg/m 2 on days 1-3 in patients older than 65 years) while 74 (51%) received a '3 þ 7' course (Idarubicin 12 mg/m 2 on days 1-3; Cytarabine 100 mg/m 2 every 12 h on days 1-7). The search for FLT3/ITDs was performed at diagnosis in either, or both, peripheral blood and bone marrow mononuclear cells, according to a previously described methodology based on capillary electrophoresis resolution of PCR-amplified fragments flanked by fluorochrome labelled primers; 7 this approach provides a careful and reproducible estimate of the size of FLT3/ITDs.
Eighty-nine patients (61%) obtained a CR after the first cycle, and 106 (72%) after the second cycle; 40 (28%) were considered as chemotherapy refractory. Induction deaths were excluded from the analysis. In the whole patient population, DFS was 9.8 months (range, 1-100) and OS was 15.6 months (range, 2-100); preliminary analysis had revealed no significant difference in either CR rate, DFS or OS between patients who had received conventional or high doses ARA-C course, so they were considered all together. Fourty-nine patients (33.6%) presented FLT3/ITDs, and 97 (66.4%) had wild-type FLT3; the median size of the ITDs was 32 nt, with a range from 17 to 214. Six patients had 2-3 ITDs (median size, 54, range 46-214 nt), and in this case only the size of the longer duplicated fragment was considered for analysis. Patients were first divided in two groups according to presenting or not FLT3/ITDs, and then according to the length of duplicated insert into a 'short' (o32 nt) or 'long' (X33 nt) ITD þ group; their main characteristics are reported in Table 1 . Patients presenting FLT3/ITDs had significantly greater leukocytosis and peripheral blood and bone marrow blastosis, while they did not differ as concerned age, anemia or thrombocytopenia; there was no significant difference in distribution among different risk categories based on conventional karyotyping (not shown in detail). The rate of CR after first or second induction cycle was similar in the two groups: 58 and 71% in the FLT3/ITDs À patients and 67 and 73% in the FLT3/ITDs þ group. On the other hand, DFS was significantly reduced from 12.8 to 4.5 months, respectively, in the FLT3/ITDs À patients as compared to ITD þ (P ¼ 0.004), while a trend, almost reaching the statistical significance, was observed for OS (from 14 to 9 months; P ¼ 0.06). According to a multivariate Cox proportional hazard analysis, age, karyotype and FLT3/ITDs predicted DFS, while age, achievement of CR, leukocytosis, and FLT3/ITDs were associated with OS. However, when patients with 'short' and 'long' FLT3/ITDs were compared each others, or entered into the multivariate analysis, no significant difference could be found among them for any of the above considered outcome parameters, except for a higher peripheral blood blast count in the 'long' ITD group (P ¼ 0.002). Similar results were obtained when the cutoff used to separate the two patient groups was 39 nt, as described by Stirewal et al.
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(not shown).
In summary, in our population of 49 FLT3/ITDs þ patients with non-APL leukemia, we failed to discover any meaningful correlation between the size of duplicated sequences and disease outcome. These results are discordant with those recently reported on 47 FLT3/ITDs mutated patients, in whom longer duplicated sequences (X39 nt) were found to harbour a greater risk of reduced OS and RFS; on the other hand, Kusec et al. 8 reported opposite results on 18 FLT3/ITDs þ patients, including also FAB-M3 leukemias, suggesting an advantage for the long ITDs group in terms of OS. Therefore, while the presence of FLT3/ITDs is an established prognostic factor for adverse outcome in AML patients, as observed also in this series, the size of duplicated insert does not seem to have the same consistent implication on disease outcome, and this issue will probably needed to be tested on larger patient populations before any definite conclusion can be drawn and translated intoHigh HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis Acute myeloid leukemia (AML) results in an accumulation of blasts with a variable degree of myeloid differentiation. Heatshock proteins belong to a group of highly conserved proteins that are predominantly synthesized following stress and fulfill important functions including transport of proteins across membranes, protein repair or degradation. Under physiological conditions, heat-shock proteins also serve as molecular chaperones during cellular differentiation. Their main function is to prevent unfolded proteins from aggregation. 1 Following stress, HSP70 is highly expressed in normal cells and cancer cells, including leukemic cells. HSP70 is involved in inhibiting apoptosis by binding to the tumor suppressor gene product p53 or interaction with apoptosis-inducing factor. Within the last years, it became obvious that HSP70 is also present on the plasma membrane of tumor cells but not on the corresponding normal tissues. 1 Depending on their intra-or extracellular localization, HSP70 mediates either protective or immune stimulatory functions. We investigated the membrane expression of HSP70 on AML blasts obtained from 92 patients (pts) with different subtypes at initial diagnosis as well as from eight patients in complete remission (CR), 14 pts in relapse and five patients with persisting disease to enlighten its prognostic relevance in AML.
Twenty-seven patients had presented with an undifferentiated leukemia (M0: n ¼ 5; M1: n ¼ 22), 38 pts with an immature granulocytic leukemia (M2: n ¼ 29; M3: n ¼ 9) and 37 pts with a monocytic leukemia (M4: n ¼ 25; M5: n ¼ 12). Seventeen patients were not French-American-British (FAB) classified. In 95 pts a pAML, and in 22 pts a sAML was diagnosed. The samples contained on average 81% blast cells. Patients studied during the course of AML had been treated according to standard treatment protocols.
Mononuclear cells were derived from aspirated bone marrow (BM) cells by Ficoll density gradient centrifugation. The mouse monoclonal antibody cmHSP70.1 conjugated with fluorescein isothiocyanate was used for the detection of HSP70 on viable cells (multimmune GmbH, Regensburg, Germany) in combination with phycoerythrin-, antigen-presenting cell-or PerCPconjugated antibodies (Beckmann-Coulter, Krefeld, Germany) directed against leukemic antigens. In cases with a high tumor load, panmyeloid markers like CD33, CD13 or CD34 in CD34 þ leukemia were used. The samples were analyzed on a FACScan (Becton Dickinson, BD, Heidelberg, Germany). Positive HSP70 expression on leukemic cells was considered in cases in which more than 10% of cells in a gate surrounding blasts, residual lymphocytes and monocytes could be identified that coexpressed HSP70 and an AML-specific marker. 2 The cytogenetic results were interpreted according to the International system of Human Cytogenetic Nomenclature. A 'favorable risk' abnormality was defined by the presence of t(8;21), t(15;17) or inv/t (16). A 'poor risk' abnormality was considered in patients with del/t 11q23 aberrations, À5/5qÀ, À7/7qÀ, 3q21 aberrations, t(6;9) or a complex karyotype (three or more numerical and/or structural abnormalities). An 'intermediate risk' was considered in patients with a normal karyotype and in patients with the remaining abnormalities. 3 Mean and s.d., median and range, two-tailed t-tests and w 2 -tests were performed using Excel 97. A 'walking cutoff' was run from the lowest to the highest level of HSP70 expression on leukemic cells. Thus, for each cutoff value the patient's samples were subdivided into two groups, with values below or above the particular cutoff, as described. 3 For each of these separations, the log-rank test was performed comparing the length of progress-free survival in the respective groups. Each test yielded a w 2 -value, representative for the
